Addressing Practical Challenges in HCV Management
Source: Addressing Practical Challenges in HCV Management

Video

Now Playing...
In this on-demand multimedia module combining slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, multidisciplinary expert faulty provide their perspectives on practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of people who inject drugs.

Sherilyn C. Brinkley, MSN, CRNP, has disclosed that she has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and consulting fees from AbbVie and Merck.

Jordan J. Feld, MD, MPH, has disclosed that he has received funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, Merck, and Regulus and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

Jason Grebely, BSc, PhD, has disclosed that he has received funds for research support from AbbVie, Cepheid, Gilead Sciences, and Merck; consulting fees from AbbVie, Gilead Sciences, and Merck; and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from AbbVie, Gilead Sciences, and Merck.

Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received funds for research support from AbbVie, Gilead Sciences, and Intercept and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Phoebe Sebhatu, PharmD, BCPS, has disclosed that she has received consulting fees from Bristol-Myers Squibb.

Downloads

  • Addressing Practical Challenges in HCV Management